


VARIABLE	Compensated n=167 (69.6%)	Recompensated n=42 (17.5%)	Decompensated n=31 (12.9%)	P values
Age, years (± SD)	66 ± 8.2	66 ± 9.4	64 ± 10	0.54
Gender, Male, n (%)	134 (80.2)	30 (71.4)	22 (71.0)	0.26
Obesity, n (%)	39 (26.9)	7 (17.5)	5 (17.9)	0.39
Comorbidities, n (%)	94 (56.3)	30 (71.4)	17 (54.8)	0.18
Etiology of liver disease, n (%)				
Viral/non-viral	76 (45.5)/91 (54.5)	12 (28.6)/30 (71.4)	8 (25.8)/23 (74.2)	0.03
Hepatitis C	67 (40.1)	12 (28.6)	6 (19.3)	0.05
MASLD	45 (26.9)	18 (42.9)	9 (29.0)	0.13
Alcoholic liver disease	20 (12.0)	4 (9.5)	6 (19.3)	0.08
Pre-IL treatment characteristics				
Child Pugh A/B, n (%)	143 (85.6)/24 (14.4)	38 (92.7)/3 (7.3)	6 (20.0)/24 (80.0)	<.0001
Mild Ascites, n (%)	-	-	28 (90.3)	<.0001
IIE grades I-II, n (%)	-	-	7 (22.6)	<.0001
ECOG 0-1, n (%)	163 (97.6)	38 (92.7)	20 (64.5)	<.0001
Median total Bilirubin, mg/dl (IQR)	1.0 (0.8-1.55)	1.0 (1.0-1.3)	1.6 (1.0-2.2)	0.003
Median Albumin, g/dl (IQR)	3.6 (3.5-4.0)	3.6 (3.5-3.6)	3.3 (3.0-3.6)	<.0001
Median INR, (IQR)	1.0 (1.0-1.2)	1.0 (1.0-1.1)	1.2 (1.1-1.4)	<.0001
Median serum AFP, ng/ml (IQR)	134.0 (11.7-1235)	607.0 (29-5843)	227.5 (16.4-1585)	0.34
AFP ≥400 ng/ml, n (%)	46 (27.5)	10 (24.4)	10 (32.3)	0.77
Macrovascular tumor invasion, n (%)	60 (35.9)	4 (9.8)	11 (35.5)	0.002
Metastatic disease, n (%)	60 (35.9)	12 (29.3)	12 (38.7)	0.67
BCLC, n (%)				
A	2 (1.2)	1 (3.3)	-	0.044
B	45 (27.9)	13 (43.3)	62 (12.9)	
C	114 (70.8)	16 (53.3)	27 (87.1)	

Abbreviations: HCC: hepatocellular carcinoma, AFP: alpha-fetoprotein; IQR: interquartile range. HE: hepatic encephalopathy.

Comparison between patients with cirrhosis presenting compensated, recompensated and decompensated cirrhosis



<https://doi.org/10.1016/j.aohep.2024.101595>

OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY

Palak J. Trivedi¹, Cynthia Levy², Kris V. Kowdley³, Stuart C. Gordon⁴, Christopher L. Bowlus⁵, Maria Carlota Londoño Hurtado⁶, Gideon M. Hirschfield⁷, Aliya F. Gulamhusien³, Eric J. Lawitz⁸, Alejandra Villamil⁹, Alma Ladron de Guevara Cetina¹⁰, Marlyn J. Mayo¹¹, Ziad H. Younes¹², Oren Shibolet¹³, Kidist K. Yimam¹⁴, Daniel S. Pratt¹⁵, Jeong Heo¹⁶, Ulrike Morgera¹⁷, Pietro Andreone¹⁸, Andreas E. Kremer¹⁹, Christophe Corpechot²⁰, Aparna Goel²¹, Adam Peyton²², Hany Elbeshbesy²³, Daria B. Crittenden²⁴, Carrie Heusner²⁴,

Sarah Proehl²⁴, Shuqiong Zhou²⁴, Charles A. McWherter²⁴

- ¹ University of Birmingham, Birmingham, Reino Unido (RU)
² University of Miami, Miami, Estados Unidos (EEUU)
³ Liver Institute Northwest, Seattle, Estados Unidos (EEUU)
⁴ Division of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Estados Unidos (EEUU)
⁵ Department of Medicine, Division of Gastroenterology and Hepatology, University of California Davis Health, Sacramento, Estados Unidos (EEUU)
⁶ The Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBEREHD, European Reference Network on Hepatological Diseases, Barcelona, España
⁷ Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, University of Toronto, Toronto, Canadá
⁸ The Texas Liver Institute, University of Texas Health, San Antonio, Estados Unidos (EEUU)
⁹ Hepatic Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
¹⁰ Centro de Investigación y Gastroenterología, Mexico City, México
¹¹ Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern, Dallas, Estados Unidos (EEUU)
¹² GastroOne, Germantown, Estados Unidos (EEUU)
¹³ The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
¹⁴ Department of Hepatology and Liver Transplantation, California Pacific Medical Center, San Francisco, Estados Unidos (EEUU)
¹⁵ Massachusetts General Hospital, Harvard Medical School, Boston, Estados Unidos (EEUU)
¹⁶ Department of Internal Medicine, Pusan National University and Biomedical Research Institute, Busan, Corea (del Sur)
¹⁷ Outpatient Clinic, Charité, Universitätsmedizin Berlin, Berlin, Alemania
¹⁸ University of Modena and Reggio Emilia, Internal Medicine, Baggiovara Hospital, Modena, Italia
¹⁹ University Hospital Zurich, Zurich, Suiza
²⁰ Reference Centre for Inflammatory Biliary Diseases and Auto-Immune Hepatitis, Saint-Antoine Hospital, Paris, Francia
²¹ Department of Medicine, Stanford University, Palo Alto, Estados Unidos (EEUU)
²² Miami Veterans Affairs Healthcare System, Miami, Estados Unidos (EEUU)
²³ Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Estados Unidos (EEUU)
²⁴ CymaBay, a Gilead Sciences Company, Fremont, Estados Unidos (EEUU)

Conflict of interest: Yes, Full disclosures sent separately.

Introduction and Objectives: Seladelpar reduces biochemical markers of cholestasis and pruritus in patients with primary biliary cholangitis. ASSURE (NCT03301506) is an ongoing, open-label, long-term Phase 3 trial of seladelpar in patients rolling over from Phase 3

RESPONSE (NCT04620733) or legacy studies (NCT03602560, NCT02955602, NCT03301506, and NCT04950764). We report interim 2-year efficacy and safety results.

Patients / Materials and Methods: Patients with insufficient response/intolerance to ursodeoxycholic acid could enroll in ASSURE. Key endpoints were composite biochemical response (alkaline phosphatase [ALP] $<1.67 \times$ upper limit of normal [ULN], ALP decrease $\geq 15\%$, and total bilirubin $\leq$ ULN) and ALP normalization. Pruritus was measured using numerical rating scale (NRS; 0–10). For patients enrolling from RESPONSE, baseline was entry to RESPONSE and analyzed as continuous seladelpar or crossover from placebo; legacy patients were analyzed separately with baseline defined as entry to ASSURE.

Results and Discussion: As of 01/2024, 158 RESPONSE and 179 legacy patients received seladelpar 10 mg daily for up to 155 weeks. In RESPONSE, 61.7% of patients met the endpoint at 12 months (M) vs 20% for placebo. In ASSURE, 61.8% (6M) and 72.4% (12M) met the composite endpoint; 75% (6M) and 93.8% (12M) of placebo crossover patients met the endpoint. In RESPONSE, ALP normalized in 25% of seladelpar and 0 placebo patients at 12M. With continued treatment, 33.3% (6M) and 17.2% (12M) had ALP normalization; 26.9% (6M) and 50% (12M) of crossover patients had ALP normalization. In ASSURE, 6-month change from baseline in pruritus NRS was similar to RESPONSE: -3.8 and -3.7 in continuous and crossover patients, respectively. At 12M and 24M, 73.2% and 69.7% of legacy patients met the endpoint in ASSURE; 42.1% and 42.4% achieved ALP normalization, and reduction in pruritus NRS was -3.8 and -3.1 , respectively. There were no treatment-related serious adverse events.

Conclusions: Seladelpar treatment led to improvements in biochemical markers and pruritus, and was well tolerated with long-term use.

<https://doi.org/10.1016/j.aohep.2024.101599>

OP-2 WILSON DISEASE (WD) DIAGNOSIS WITH NEXT-GENERATION SEQUENCING (NGS) IN CLINICAL PRACTICE: A PILOT STUDY

Marta Mitiko Deguti¹,
Michele Soares Gomes Gouvêa²,
Debora Raquel Benedita Terrabuio¹,
Thiago Ferreira Araújo², Gilda Porta³,
Egberto Reis Barbosa¹,
Eduardo Luiz Rachid Cançado¹

¹ HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA USP, SAO PAULO, Brasil

² LIM-07 Laboratório de Gastroenterologia e Hepatologia Tropical do IMT da FACULDADE DE MEDICINA DA USP, SAO PAULO, Brasil

³ INSTITUTO DA CRIANÇA DO HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA USP, SAO PAULO, Brasil

Conflict of interest: Yes, Ultragenyx has provided 25 kits for copper panel genotyping by NGS at Mendelics laboratory

Introduction and Objectives: Wilson disease (WD) is an autosomal recessive disorder caused by a defect in the ATP7B protein, leading to copper overload. ATP7B genotyping has been performed by Sanger method, but NGS techniques have recently become available. Our aim was to analyze the impact of Sanger direct sequencing and NGS in the diagnosis of WD.

Patients / Materials and Methods: A series of 287 WD patients included 160 individuals who provided DNA after informed consent. All patients met ≥ 4 points of the European WD scoring system. DNA for Sanger sequencing was extracted from peripheral leukocytes and

for NGS from oral cells using a buccal swab. ATP7B mutations were identified in 135 patients by Sanger sequencing only, in 17 by NGS and in 8 by both methods. Sanger sequencing was performed as previously published (Deguti et al, 2004). In targeted NGS using a "copper panel" (Laboratório Mendelics), libraries were prepared with Illumina DNA with enrichment, target regions were captured using specific probes (Twist Biosciences v.3) for all exons/intronic regions, and variants and indels were identified using GATL v4 program and CNVs using ExomeDepth.

Results and Discussion: Of the 320 alleles analyzed, the most frequent mutations were p.A1135fs (26.7%), L708P (15.8%), p.H1069Q (5.3%) and p.M645R (3.1%). The remaining 49.1% of alleles had 38 distinct disease-causing mutations, each with a frequency of $<3.0\%$. Sanger sequencing detected a mutation in 264/286 alleles (92.3%), while the NGS method detected a mutation in 50/50 (100%). The table shows the results of the 8 patients genotyped with both methods.

Conclusions: The Sanger direct sequencing methods were laborious and detected mutations in 92.3% of ATP7B alleles, while NGS techniques yielded 100%, impacting the WD score by up to 4 points. This can be crucial in difficult and potentially severe cases.

<https://doi.org/10.1016/j.aohep.2024.101600>

OP-3 ASSESSING TREATMENT ELIGIBILITY EXPANSION UNDER THE 2024 WHO GUIDELINES FOR CHRONIC HEPATITIS B

Manuel Mendizabal¹, Constanza D Sabate²,
Esteban Gonzalez Ballerga³, Fernando Gruz⁴,
Ezequiel Ridruejo⁵, Alejandro Soza⁶,
Jaime Poniachik⁷, Grace Vergara⁸, Victoria Mainardi⁹,
Gabriel Mezzano¹⁰, Fernando Bessone¹¹,
Margarita Anders¹², Mario G Pessoa¹³,
Fernando Cairo¹⁴, Nelia Hernandez¹³,
Melisa Dirchwolf¹⁵, Hugo Cheinquer¹⁶,
Melina Susana¹³, Luis Rondeau¹³, Grabriel Rifrani¹¹,
Herman Aguirre¹⁰, Daniela Chiodi¹³, Carla Enrique¹²,
Lucia Navarro¹⁴, Eugenia Labaronnie¹⁵,
Patricia M Zitelli¹³, Alexandre de Araujo¹⁶,
Antonella Olivetti¹³, Daniela Simian⁷, Diego Giunta⁸,
Marcelo Silva¹, Sebastian Marciano⁸

¹ Hospital Universitario Austral, Pilar, Argentina

² HOSPITAL UNIVERSITARIO AUSTRAL, Pilar, Argentina

³ Hospital de Clínicas, Buenos Aires, Argentina

⁴ Sanatorio Anchorena (San Martín), Buenos Aires, Argentina

⁵ CEMIC, Buenos Aires, Argentina

⁶ Universidad Catolica, Santiago, Chile

⁷ Universidad de Chile, Santiago, Chile

⁸ Hospital Italiano, Buenos Aires, Argentina

⁹ Hospital Militar, Montevideo, Uruguay

¹⁰ Hospital del Salvador, Santiago, Chile

¹¹ Hospital Centenario, Rosario, Argentina

¹² Hospital Aleman, Buenos Aires, Argentina

¹³ Hospital de Clínicas, San Pablo, Brasil

¹⁴ Hospital El Cruce, Florencio Varela, Argentina

¹⁵ Hospital Privado de Rosario, Rosario, Argentina

¹⁶ Universidad de Rio Grande, Porto Alegre, Brasil

Conflict of interest: No

Introduction and Objectives: The 2024 WHO guidelines for chronic hepatitis B (CHB) aim to expand and simplify treatment eligibility, but these criteria have not been assessed. We aimed to estimate treatment eligibility and uptake according to country-specific